Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelabresib - MorphoSys

Next Previous
Drug Profile

Pelabresib - MorphoSys

Alternative Names: CPI-0610; DAK-539

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Constellation Pharmaceuticals
  • Developer Constellation Pharmaceuticals; MorphoSys; The Leukemia & Lymphoma Society
  • Class Amides; Antihaemorrhagics; Antineoplastics; Benzazepines; Chlorinated hydrocarbons; Oxazoles; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelofibrosis
  • Phase II Essential thrombocythaemia; Leukaemia; Myelodysplastic syndromes
  • No development reported Haematological malignancies; Solid tumours
  • Discontinued Lymphoma; Multiple myeloma

Most Recent Events

  • 09 Jan 2025 Constellation Pharmaceuticals completes a phase I/II trial in Essential Thrombocytopenia in Italy, Netherlands, France, Canada, Belgium, Germany, United Kingdom, Poland, USA (PO) (NCT02158858)
  • 09 Jan 2025 Constellation Pharmaceuticals completes a phase I/II trial in Myelofibrosis (Combination therapy, Second-line tehrapy or greater) in Italy, Netherlands, France, Canada, Belgium, Germany, United Kingdom, Poland, USA (PO) (NCT02158858)
  • 09 Jan 2025 Constellation Pharmaceuticals completes a phase I/II trial in Myelofibrosis (First-line therapy, Combination therapy) in Italy, Netherlands, France, Canada, Belgium, Germany, United Kingdom, Poland, USA (PO) (NCT02158858)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top